, Singapore

Daily Markets Briefing: STI ends flat

Index likely to pull back towards 3229, says analyst.

OCBC Investment Research noted:

While the STI ended flat yesterday, we note that the total value traded fell below S$1.0b; but could also be due to extended Good Friday break.

However if that is the case, we could see a stronger profit-taking interest, which could send the index pulling back towards 3229 (23.6% retracement of the 2931-3321 rally).

For now, the initial support sits at 3300, ahead of 3278 (centre of Bollinger band). On the upside, recent 3321 high remains the initial (potentially formidable) cap.

IG Markets Singapore said:

In Singapore, we expect trading activity to remain light and the STI flat as a result.

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare